Dong Lu

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

This paper evaluates two fluorescent tracers for use in TR-FRET and NanoBRET assays, showing they can be used across platforms with consistent performance.

This paper develops a first-in-class RIPK1 degrader, LD4172, which enhances antitumor immunity by promoting immunogenic cell death and sensitizing tumors to anti-PD1 therapy.

This study introduces lysineless HiBiT-RR and nLucK0 tagging systems to reduce degradation artifacts in monitoring protein degradation, showing HiBiT-RR retains sensitivity and nLucK0 shows different degradation patterns than nLucWT.

The paper identifies regulatory degeneration in Alzheimer's disease using RNA-seq data and suggests HDAC1 as a potential drug target.

This paper uses module analysis of single-patient differential expression signatures to identify AD risk loci in a small cohort, finding more risk loci than using all patients.

This study identifies accumulated transcriptional regulation degeneration as a key contributor to Alzheimer's disease progression and clinical outcomes.